Samsara BioCapital, L.P.

This profile gathers the share dealings of Samsara BioCapital, L.P. in LENZ Therapeutics, Inc. Between 29 June 2021 and 11 April 2022, the trades on record add up to 8 filings.

Every open-market trade on record is a purchase: 7 purchases worth €4.8M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2022: 3 purchases and no sales on the market.

A typical purchase (the median) is worth €517k. On 1 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 13 April 2022, the filings show an open-market purchase worth €279k in LENZ Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.